REXAHN PHARMACEUTICALS, INC. REXN Cash Flow

Rexahn pharmaceuticals, inc. (REXN)
CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows from Operating Activities:
Net loss
-6,879	-8,635	-9,883	-13,262	-14,636	-14,368	-14,844	-10,543	-5,758	-25,294	-22,227	-24,056	-26,769	-9,307	-11,634	-12,793	-14,261	-14,384	-13,742	-11,621	-8,192	-18,521	0	0	0	-9,048	-11,344	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Beneficial conversion feature
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Compensatory stock
-	-	-	-	-	22	22	30	30	31	31	45	61	97	97	110	94	102	102	129	129	409	0	0	0	0	0	0	0	0
Depreciation and amortization
38	40	42	43	45	48	48	49	48	42	39	37	35	32	31	29	27	27	25	22	25	28	0	0	0	41	45	0	0	0
Loss on sale of equipment
-	-9	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of premiums and discounts on marketable securities, net
94	108	82	43	-5	-39	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of premiums and discounts on marketable securities, net
-	-	-	-	-	-	-	-	-	-	41	20	14	22	30	39	37	30	0	0	0	-	-	-	-	-	-	-	-	-
Stock-based compensation
372	456	762	953	1,092	1,228	1,099	1,045	1,066	1,044	1,135	1,277	1,340	1,409	1,331	1,187	1,108	1,037	954	892	752	608	0	0	0	527	638	0	0	0
Amortization and termination of deferred research and development arrangement
-	-	-	-	-	-375	-393	-412	-431	-75	-75	-75	-75	-75	-75	-75	-75	-75	-75	-115	-201	-233	0	0	0	0	-	-	-	0
Unrealized loss (gain) on fair value of warrants
-694	-2,265	-3,977	-3,024	-3,692	-5,546	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized (gain) loss on fair value of warrants
-	-	-	-	-	-	-	-	-	-	-7,459	-9,612	-13,015	5,529	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Note receivable (Note 5)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28	28	0	0	0
Realized losses on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	-3	0	0	0
Unrealized (gain) loss on fair value of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-4,984	-4,778	0	0	0
Unrealized gain on fair value of put feature on common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Financing expense
-	-	-	-	-	-	-	-	-	-	-	-	-	313	0	0	0	-	-	-	-	206	0	0	0	0	97	0	0	0
Amortization of deferred lease incentive
-	-	-	-	-	-	-12	-12	-12	-12	-12	-12	-12	-12	-12	-12	-12	-12	-12	-12	-12	-12	0	0	0	-20	-20	0	0	0
Deferred rent
-	-	-	-	-	-	-19	-13	-11	-10	-11	-14	-13	-12	-11	-10	-9	-8	-7	-6	-5	7	0	0	0	12	8	0	0	0
Loss on impairment of intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Changes in assets and liabilities:
Prepaid expenses and other assets
-691	-608	-414	-314	-230	-230	-122	166	266	696	475	203	19	-613	-673	-281	-39	495	749	406	291	249	0	0	0	-437	-373	0	0	0
Research tax credit receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	145	0	0	0
Accounts payable and accrued expenses
-1,009	-1,886	-1,965	-1,460	-802	-81	992	1,577	1,333	1,351	553	9	-1,568	-778	-1,452	-1,374	534	202	1,512	1,628	1,871	1,525	0	0	0	-1,919	-635	0	0	0
Deferred revenue
450	1,500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other, net
-6	-3	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Cash Used in Operating Activities
-7,118	-10,277	-13,184	-14,973	-17,620	-18,838	-17,923	-17,203	-16,849	-15,420	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Cash Used in Operating Activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-13,227	-16,141	-17,522	-16,862	-17,351	-15,856	-13,955	-12,503	-11,041	0	0	0	-15,020	-15,530	0	0	0
Cash Flows from Investing Activities:
Restricted cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-196	0	0	0	-2,083	1,029	0	0	0
Purchase of equipment
-	19	19	55	49	39	93	60	73	75	21	19	8	8	18	57	58	62	63	39	45	41	0	0	0	16	16	0	0	0
Sale of equipment
-	5	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of marketable securities
-	8,887	0	0	0	-	-	-	-	21,017	15,008	22,034	9,031	8,747	15,914	8,889	8,889	7,908	0	0	0	-	-	-	-	8,000	8,000	0	0	0
Redemption of marketable securities
12,000	12,000	11,000	11,700	11,950	11,950	12,950	12,250	12,000	11,720	13,400	15,520	15,000	13,240	11,460	13,340	13,500	17,525	0	0	0	-	-	-	-	8,500	8,500	0	0	0
Net Cash (Used in) Provided by Investing Activities
-	-	-	-	-	-	-	-	-	-	-	-	-	4,483	-4,472	4,393	4,551	9,554	11,598	-15,893	-18,453	-22,661	0	0	0	-	-	-	-	-
Payment of licensing fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Net Cash Provided by (Used in) Investing Activities
11,993	3,098	2,098	2,763	3,018	11,910	6,848	6,180	-7,085	-9,372	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	2,567	-545	0	0	0
Cash Flows from Financing Activities:
Issuance of common stock and units, net of issuance costs
-	7,653	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock and units, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	10,122	0	0	0	-	-	-	-	18,634	0	0	0	0	13,220	0	0	0
Proceeds from exercise of stock warrants
-	-	-	-	-	-	-	-	-	5,354	0	0	0	-	-	-	-	-	-	-	-	5,947	0	0	0	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	708	708	708	894	258	0	0	0	41	59	0	0	0
Net Cash Provided by Financing Activities
-	-	-	-	-	-	-	-	-	-	-	-	-	10,122	16,556	11,036	12,045	8,170	1,736	1,714	1,613	24,840	0	0	0	-	-	-	-	-
Proceeds from exercise of stock warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	317	0	0	0
Proceeds from long-term debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Proceeds from research and development arrangement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Purchase of treasury stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Net Cash Provided by Financing Activities
-	7,653	0	0	0	-	-	-	-	22,113	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	41	13,597	0	0	0
Net Increase (Decrease) in Cash and Cash Equivalents
4,875	475	3,340	2,215	-175	-154	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Decrease in Cash and Cash Equivalents
-	-	-	-	-	-	-	-	-	-2,679	-166	912	22	1,379	-4,058	-2,092	-265	373	-2,521	-28,133	-29,343	-8,861	0	0	0	-12,411	-2,478	0	0	0
Supplemental Cash Flow Information
Operating cash flows paid for amounts included in the measurement of lease liabilities
150	197	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Non-cash financing and investing activties:
Warrants issued
-	4,735	0	0	0	-	-	-	-	-	-	-	-	4,364	0	0	0	-	-	-	-	3,691	0	0	0	0	2,924	0	0	0
Operating lease right-of-use assets obtained in exchange for lease obligations:
-	380	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant liability extinguishment from exercise of warrants
-	-	-	-	-	-	-	-	-	8,052	0	0	0	-	-	-	-	-	-	-	-	10,137	0	0	0	-	-	-	-	-
Stock subscription receivable from warrants exercised
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Put feature on common stock issued
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Dilutive issuances of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Warrant liability extinguishment from exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	243	0	0	0
Leasehold improvement incentive
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Settlement of lawsuit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0